Cargando…

Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy

BACKGROUND: The majority of urothelial cancers (UC) harbor alterations in retinoblastoma (Rb) pathway genes that can lead to loss of Rb tumour suppressor function. Palbociclib is an oral, selective inhibitor of CDK 4/6 that restores Rb function and promotes cell cycle arrest. METHODS: In this phase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rose, Tracy L., Chism, David D., Alva, Ajjai S., Deal, Allison M., Maygarden, Susan J., Whang, Young E., Kardos, Jordan, Drier, Anthony, Basch, Ethan, Godley, Paul A., Dunn, Mary W., Kim, William Y., Milowsky, Matthew I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189143/ https://www.ncbi.nlm.nih.gov/pubmed/30293995 http://dx.doi.org/10.1038/s41416-018-0229-0

Ejemplares similares

A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Kim, Stephanie I., et al.
Publicado: (2021)

Correction: A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Kim, Stephanie I., et al.
Publicado: (2021)

Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma
por: Osterman, Chelsea K., et al.
Publicado: (2020)

Urothelial Cancer With Occult Bone Marrow Metastases and Isolated Thrombocytopenia
por: Alva, Ajjai, et al.
Publicado: (2015)

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes
por: Grivas, Petros, et al.
Publicado: (2018)

Case report: Immune-mediated meibomian gland dysfunction following pembrolizumab therapy for advanced urothelial carcinoma
por: Nguyen, Charles B., et al.
Publicado: (2022)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab, Moataz, et al.
Publicado: (2016)

Secondary Immune Thrombocytopenia in Metastatic Renal Cell Carcinoma: A Case Report and Discussion of the Literature
por: Cockrell, Dillon C., et al.
Publicado: (2020)

Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival
por: Ramos, Jorge D., et al.
Publicado: (2016)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Palbociclib in metastatic breast cancer: current evidence and real-life data
por: Serra, Francesco, et al.
Publicado: (2019)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
por: Tassinari, Elisa, et al.
Publicado: (2022)

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
por: Rosenberg, Jonathan E., et al.
Publicado: (2018)

Palbociclib Plus Letrozole for the Treatment of Metastatic Breast Cancer: An Illustrative Case Scenario
por: Orbaugh,1, Kristi, et al.
Publicado: (2016)

Metastatic urothelial carcinoma()()
por: Gómez-Moyano, Elisabeth, et al.
Publicado: (2021)

Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study
por: Di Lorenzo, Giuseppe, et al.
Publicado: (2015)

Impact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma
por: Kohei, Naoki, et al.
Publicado: (2018)

Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma
por: Abe, T, et al.
Publicado: (2019)

Correction to: Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience
por: Rose, Tracy L., et al.
Publicado: (2022)

Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib
por: Dhakal, Ajay, et al.
Publicado: (2020)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
por: Duan, Chenxin, et al.
Publicado: (2021)

Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma
por: Xue, Zhichao, et al.
Publicado: (2020)

Combination of palbociclib and radiotherapy for glioblastoma
por: Whittaker, Shane, et al.
Publicado: (2017)

Palbociclib-Induced Liver Failure
por: Atallah, Rami, et al.
Publicado: (2020)

Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer
por: Damrauer, Jeffrey S., et al.
Publicado: (2022)

A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma
por: Naiki, Taku, et al.
Publicado: (2017)

Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data
por: Fischer, Christine, et al.
Publicado: (2020)

Erratum to: Outcome of maintenance systemic chemotherapy with drug-free interval for metastatic urothelial carcinoma
por: Abe, T, et al.
Publicado: (2020)

Prospective Cohort Study of Palbociclib Treatment in Postmenopausal Patients With Unresectable and Metastatic Hormone Receptor-Positive Breast Cancer: Study Protocol for a CSPOR-BC Palbociclib Cohort Trial
por: Narui, Kazutaka, et al.
Publicado: (2022)

Stevens-Johnson syndrome–like eruption from palbociclib in a patient with metastatic breast cancer
por: Karagounis, Theodora, et al.
Publicado: (2018)

Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
por: Sun, James, et al.
Publicado: (2021)

Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
por: Odabas, Hatice, et al.
Publicado: (2023)

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
por: El-Botty, Rania, et al.
Publicado: (2023)

Metachronous Bilateral Testicular Leydig-Like Tumors Leading to the Diagnosis of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)
por: Vukina, Josip, et al.
Publicado: (2015)

Organ-Specific Therapeutic Effect of Paclitaxel and Carboplatin Chemotherapy After Platinum-Based Chemotherapy and Pembrolizumab for Metastatic Urothelial Carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2020)

Tailored Selection of First-Line Cisplatin-Based Chemotherapy in Patients with Metastatic Urothelial Carcinoma of Bladder
por: Hsieh, Meng-Che, et al.
Publicado: (2016)

Erratum: Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy
por: Abe, Takashige, et al.
Publicado: (2020)

Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer
por: Uchida, Hideaki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6mra32iidov2t5tt6jl1m5ungj